The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback